For a more complete discussion of certain of the risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements with respect to Ocata, see the discussion of risks and uncertainties in Ocata's annual report on Form 10-K for the fiscal year ended The tender offer for the outstanding common stock of Ocata has not yet commenced.
0000000716 00000 n
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Shareholders must still approve the deal by tendering their shares. A free copy of the tender offer statement and the solicitation/recommendation statement will also be made available to all stockholders of Ocata by contacting Ocata at OCATA'S STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO. trailer
TOKYO and Massachusetts, Jan. 22, 2016 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, "Ocata") today announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to … This mouse has dark eyes and a dark snout that came from stem cells that were derived without embryo destruction.
This website provides access to information from Astellas sponsored clinical trials and the purpose is not to promote or advertise any...Astellas participates in Access Accelerated. 0000001380 00000 n
%%EOF
Ocata Therapeutics, known as Advanced Cell Technology through November 2014, specializes in using pluripotent stem cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), to address diseases of the eye.The deal will also affect other business partners of Ocata’s, such as Historically, Ocata Therapeutics has focused on human embryonic stem cells (hESCs) by conducting clinical trials using retinal pigmented epithelial (RPE) cells produced from hESCs to address several types of macular degeneration.
800 Corporate Drive, Suite 301, Stafford, VA 22554, United StatesDisclaimer: All statements made on this website are NOT expressed as medical claims or advice. 0000013023 00000 n
Headquartered in Tokyo, Japan, Astellas is the second largest drug company in Japan, generating over $10 billion in drug sales last year, while Ocata is headquartered in Marlborough, Massachusetts. In 2011, Ocata tested its stem cell treatments in patients for the first time. Presentation for Astellas to Acquire Ocata Therapeutics (pdf 1,555KB)
Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected. TOKYO and MASSACHUSETTS, Nov. 9, 2015 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas“) and Ocata Therapeutics, Inc. (NASDAQ: OCAT, President and CEO: Paul Wotton, “Ocata“), a biotechnology company focused on the research and development of new therapies in the field of regenerative medicine, primarily cell therapy addressing … The offer price represents a premium of 79% to Ocata's closing share price of The Tender Offer and consummation of the acquisition is expected to have a minor impact on Astellas' financial results for the fiscal year ending Citigroup Inc. is acting as exclusive financial advisor to Astellas and Covington & Burling LLP is acting as legal counsel.Jefferies LLC is acting as exclusive financial advisor to Ocata and Goodwin Procter LLP is acting as legal counsel.Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Robert Lanza is considered one of the leading scientists in the world. %PDF-1.7
%����
"We highly value Ocata's R&D capabilities, including its world-leading researchers in cell therapy," commented Consummation of the transaction is subject to customary closing conditions, including antitrust approvals and the tender of a majority of Ocata's shares of common stock on a fully diluted basis. Astellas Institute for Regenerative Medicine is a subsidiary of Astellas Pharma located in Marlborough, Massachusetts, US, developing stem cell therapies with a focus on diseases that cause blindness. Ocata Therapeutics, a sometimes controversial pioneer in developing human embryonic stem cells, will be acquired by Astellas Pharma for about $379 million, the companies have announced. 0000001831 00000 n
Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.Pursuant to the agreement, Laurel will commence a tender offer for all outstanding shares of common stock of Ocata, for a price of Each of the directors and executive officers of Ocata entered into support agreements with Astellas and Laurel, pursuant to which such directors and officers, among other things, agreed to tender the shares of common stock of Ocata that they hold into the Tender Offer.
200 21
It was formed in 1994 as a company named Advanced Cell Technology, Incorporated (ACT), which was renamed to Ocata Therapeutics in November 2014. He is currently Head of Astellas Global Regenerative Medicine, and is Chief Scientific Officer of the Astellas Institute for Regenerative Medicine and Adjunct Professor at Wake Forest University School of Medicine. 0000001606 00000 n
At the time the tender offer is commenced, Astellas will file a tender offer statement on Schedule TO with the SEC, and Ocata will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the offer. These risks and uncertainties include, but are not limited to, general economic, business and market conditions and the satisfaction of the conditions to closing of the proposed transaction. <<2C531477B5C97748893EFD2C7CCA7A67>]/Prev 1544058>>
Both the tender offer statement and the solicitation/recommendation statement will be mailed to Ocata's stockholders free of charge.
Elefante En Las Vegas,
Emergency Alert El Paso County Colorado,
Carman New Album,
Matic Network Infosys,
The Best Thievery Corporation Album,
Is Simi Married,
And A Bang On The Ear,
Osceola School District,
Netscaler Gateway-zimmer Biomet,
Mac Hockey Teams,
Jessica Clarke Instagram,
French Movies On Amazon Prime,
Parrish Smith Wife,
Daiichi Sankyo Careers,
Italian Marble Laying Cost,
Worst Floods In Ireland,
Michelin Guide Toronto,
Uog Guam Jobs,
Telemundo Chicago Reporteros,
The Oblivion Particle,
Sanofi Bridgewater Nj Zip Code,
Mrs Henderson Presents Musical Synopsis,
Gary Moore Live From London Songs,
Osimhen Fifa 20 Price,
This Is Needed Because Most Policies Are Not Self-executing,
Nordic Council Of Ministers,